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Abstract
Huntington disease (HD) is caused by expansion of a polyglutamine (polyQ) domain in the protein
known as huntingtin (htt), and the disease is characterized by selective neurodegeneration.
Expansion of the polyQ domain is not exclusive to HD, but occurs in eight other inherited
neurodegenerative disorders that show distinct neuropathology. Yet in spite of the clear genetic
defects and associated neurodegeneration seen with all the polyQ diseases, their pathogenesis
remains elusive. The present review focuses on HD, outlining the effects of mutant htt in the
nucleus and neuronal processes as well as the role of cell-cell interactions in HD pathology. The
widespread expression and localization of mutant htt and its interactions with a variety of proteins
suggest that mutant htt engages multiple pathogenic pathways. Understanding these pathways will
help us to elucidate the pathogenesis of HD and to target therapies effectively.
Background
Huntington's disease (HD) was first described by the
American physician George Huntington in 1872. The dis-
ease is a genetic disorder of the central nervous system,
with symptoms usually consisting of uncontrolled move-
ments, emotional disturbances, and mental deterioration
[1,2]. Psychiatric abnormalities, including depression,
anxiety, apathy, and irritability, are often an early mani-
festation of HD, appearing before the characteristic neuro-
logic symptoms of overt chorea, or spasmodic movements
of the limbs and facial muscles [3,4]. Patients also demon-
strate cognitive deficits or dementia as well as weight loss.
The age at onset is variable, but most HD patients first
show symptoms between the ages of 30 and 40 years
[5,6]. Clinical features develop progressively, with an
increase in choreic movements, dementia, and other
motor deficits including dystonia and rigidity. HD termi-
nates in death within 10–20 years after initial symptoms
appear. While there are medications to help manage the
signs and symptoms of HD, treatments that can actually
prevent the physical and mental decline associated with
HD are lacking.
HD is inherited as an autosomal dominant condition and
is found in every country of the world. In the United States
alone, about 30,000 people have HD, making its preva-
lence about 1 in every 10,000 persons. At least 150,000
others carry a 50 percent risk of developing the disease,
and thousands more of their relatives live with the possi-
bility that they might develop HD.
The hunt for the HD gene involved an intense molecular
genetics research effort by investigators cooperating
around the globe. For 10 years, scientists were focused on
a segment of chromosome 4p16.3, and they succeeded in
isolating the HD gene in 1993 [7]. The genetic defect
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responsible for the disease is expansion of a CAG repeat in
the gene coding for the HD protein, huntingtin (htt). This
CAG repeat is an unstable triplet repeat DNA sequence,
and its length is inversely correlated with the age at onset
of disease, especially in juvenile HD cases, when the
repeat length is often >60 CAG units [8-10]. Expanded
CAG repeats have been found in 8 other inherited neuro-
degenerative diseases, as well, including spinocerebellar
ataxia (SCA) and spinobulbar muscular atrophy (SBMA)
[11-13]. It is now clear that expansion of this repeat in var-
ious genes can cause distinct neurodegenerative pathol-
ogy in different disorders.
The CAG repeat is translated into a polyglutamine
(polyQ) domain in the disease proteins. Human htt is a
large protein consisting of 3144 amino acids. A normal
polyQ domain, which in htt begins at amino acid position
18, typically contains 11–34 glutamine residues in unaf-
fected individuals, but this expands to more than 37
glutamines in HD patients. The length of the polyQ repeat
varies among species. For example, mouse htt has 7
glutamines, whereas pufferfish htt contains only 4 [14],
which suggests that the polyQ domain may not be essen-
tial, but that it can regulate protein function. Consistently,
deletion of the CAG repeat in the HD gene only results in
subtle behavioral and motor phenotypes in mice [15].
Htt is ubiquitously expressed in the brain and body and
distributed in various subcellular regions [16-19]. Its
sequences do not show homology to other proteins of
known function. One structural feature of htt that has
been identified is the presence of HEAT repeats [20],
which are sequences of ~40 amino acids that occur multi-
ple times within a given protein and are found in a variety
of proteins involved in intracellular transport and chro-
mosomal segregation [21]. Several lines of evidence also
suggest that htt is involved in intracellular trafficking and
various cellular functions. For example, htt is associated
with a number of subcellular organelles [16-18,22]. Con-
sistent with this, htt is known to interact with a variety of
proteins that can be grouped according to whether they
are involved in gene transcription, intracellular signaling,
trafficking, endocytosis, or metabolism [14,19]. Identifi-
cation of these htt-interacting proteins suggests that htt
may function as a scaffold involved in coordinating sets of
proteins for signaling processes and intracellular trans-
port.
The essential role of htt has been established using HD
gene knockout mice. In this model, the absence of htt
causes cell degeneration and embryonic lethality [23-25].
Conditional knockout mice also show degeneration in
adult cells [26]. These observations have led to the theory
that a loss of htt function may contribute to the neuropa-
thology of HD [27]. However, there is more evidence to
support the theory wherein mutant htt gains a toxic func-
tion. For example, heterozygous HD knockout mice are
known to live normally. Further, identification of the HD
gene has allowed for generation of various animal models
in which mutant htt is expressed in the presence of endog-
enous normal htt, and these transgenic mice still develop
neurological symptoms and die early, even when endog-
enous normal htt is expressed at the normal levels
[28,29]. In addition, mutant htt can rescue the embryonic
lethal phenotype of htt-null mice [30], which also sug-
gests the HD mutation can lead to neuronal toxicity, inde-
pendent of the essential function of htt.
Neuropathology of Huntington's disease
Despite its widespread distribution, mutant htt causes
selective neurodegeneration, which occurs preferentially
and most prominently in the striatum and deeper layers of
the cortex in the early stages of HD [31]. In advanced
stages, other brain regions, such as the hippocampus,
hypothalamus, cerebellum, amygdala, and some thalamic
nuclei, are also affected. Among these other brain regions,
the lateral tuberal nucleus of the hypothalamus exhibits
severe atrophy [32].
The neurons that are most severely affected in HD are stri-
atal projection neurons, which send their axons to differ-
ent brain regions. These are the GABAergic medium-sized
spiny neurons (MSNs), and they constitute 95% of all stri-
atal neurons. MSNs receive abundant glutamatergic input
from the cortex and primarily innervate the substantia
nigra and globus pallidus. Thus, their preferential loss in
HD is thought to be the result of glutamate excitotoxicity.
Consistently, there is a relative sparing of interneurons
that colocalize somatostatin, neuropeptide Y, and
NADPH diaphorase, as well as of cholinergic interneurons
and a subclass of GABAergic neurons that contain parval-
bumin [31,33,34].
Another important pathological feature in the postmor-
tem brains of HD patients is gliosis [35-37]. Reactive glia
or gliosis often occurs in response to neuronal injury. For
example, neuronal degeneration is evidenced by a dra-
matic elevation in the density of large glia [38]. Marked
astrogliosis and microgliosis were observed in caudate
and internal capsule samples of HD patients, but not in
normal brain. In the striatum and cortex, reactive micro-
glia also occurred in all grades of pathology, accumulated
with increasing grade, and grew in density in relation to
the degree of neuronal loss [35,37]. Thus, reactive micro-
glia were considered to be an early response to changes in
neuropil [37]. While reactive gliosis does represent an
early neuropathological event in HD, glial pathology can
also impact neuronal viability. Indeed, gliosis is a patho-
logical feature in several HD mouse models that lack overt
neuronal cell degeneration. These models include trans-Molecular Neurodegeneration 2006, 1:19 http://www.molecularneurodegeneration.com/content/1/1/19
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genic mice expressing N-terminal mutant htt [39-41] and
knock-in mice that express full-length mutant htt [42,43].
Since the discovery of the HD gene, various antibodies to
htt have been generated to characterize the distribution of
mutant htt. Immunostaining of brains from transgenic
mice that express mutant htt revealed nuclear inclusions
[28]. Similar nuclear inclusions were then identified in
the brains of HD patients [44,45]. Subsequently, the accu-
mulation of expanded polyQ-containing proteins in the
nucleus and nuclear inclusions were found to be common
pathological features of other polyglutamine diseases [11-
13]. The role of these nuclear inclusions in HD remains
controversial, since their formation is correlated with dis-
ease progression, but is not associated with neuronal
degeneration [45-47]. Further, several studies have shown
that htt inclusions are protective against htt toxicity in cul-
tured cells [48,49]. Despite the controversy surrounding
their exact roles, htt inclusions reflect protein misfolding
caused by expanded polyQ domains and represent a path-
ological hallmark for the accumulation of toxic mutant
htt. It is also noteworthy that normal htt is predominantly
localized in the cytoplasm, whereas mutant htt with its
expanded polyQ domain accumulates in the nucleus.
Therefore, nuclear inclusions reflect the aberrant accumu-
lation of mutant htt in the nucleus, as well. Importantly,
HD also features abundant cytoplasmic aggregates local-
ized in the neuronal processes (neuropil aggregates),
including axons and dendrites [29,45,50-54]. In the early
stage of disease, the brains of HD patients contain more
dystrophic neurites or neuropil aggregates than nuclear
inclusions [44,45]. In addition, the progressive formation
of neuropil aggregates is correlated with disease progres-
sion in transgenic mice [50-52,54], and neuropil aggre-
gates are associated with axonal degeneration in HD
mouse brains [40,52]. Taken together, the localization of
htt aggregates in the nucleus and neuronal processes
reveals that mutant htt elicits toxicity in both the nucleus
and cytoplasm.
A number of mouse models have provided in vivo evi-
dence for the pathology of HD. Several transgenic HD
mice were generated using either the human htt promoter
or neuronal promoters. For example, transgenic mice R6/
2 express exon1 htt with 115–150 glutamine repeats
(115–150Q) under the control of the human HD gene
promoter [28]. YAC transgenic mice use the human HD
gene promoter to drive the expression of full-length
mutant htt [55,56]. N171-82Q transgenic mice express
the first 171 amino acids with 82Q under the neuronal
prion promoter [29]. These transgenic mice have been
widely studied and found to have neurological and behav-
ioral phenotypes similar to those of HD patients. There
are also HD repeat knock-in mouse models, which are
generated by inserting an expanded repeat into the endog-
enous mouse HD gene [43,57-59]. However, most HD
mouse models do not show the overt neurodegeneration
seen in human HD patients, even though some models
display severe neurological symptoms and early death
[28,29]. It is possible that the short life span of the mouse
does not allow sufficient time for the development of
obvious neurodegeneration, although some earlier patho-
logical events do occur.
HD mouse models also suggest that small htt fragments
containing expanded polyQ are more toxic than larger
fragments. This fits with the finding that small N-terminal
htt fragments are misfolded and form aggregates and
inclusions in the brains of HD patients [44,45]. It is evi-
dent that proteolysis of htt generates multiple N-terminal
htt fragments in HD repeat knock-in mouse brain [60]. A
number of protease cleavage sites, including those for cap-
sase-3, cspase-6, calpain, and unknown aspartic protease,
have been found within the first 550 amino acids of htt
[56,61-64]. However, most studies used transfected pro-
teins to identify these cleavage sites, and the nature of
toxic N-terminal htt fragments generated organically in
the HD brain is still being explored. It is likely that the
proteolysis of full-length htt generates a number of N-ter-
minal htt fragments. The decreased activities of the protea-
somes and chaperones, which are responsible for clearing
out misfolded and toxic peptides, promote the accumula-
tion of htt fragments in aged neurons. In the meantime,
an expanded polyglutamine tract causes them to misfold
and aggregate in the nucleus and neuronal processes. The
accumulation of mutant htt in the nucleus and neuronal
processes therefore suggests that these subcellular regions
are the primary sites for mutant htt to elicit its toxicity.
Nuclear effect of mutant huntingtin
The nuclear inclusions of mutant htt led investigators to
study the mechanisms for this phenomenon. Although
some immunostaining and nuclear fractionation studies
have shown that normal htt is also localized in the
nucleus [65,66], it is clear that the majority remains in the
cytoplasm. Moreover, nuclear htt aggregates can only be
recognized by antibodies against the N-terminal region of
htt [44,45]. Furthermore, isolation of nuclear fractions
from HD knock-in mice, which express full-length mutant
htt under the endogenous mouse HD gene, provides evi-
dence that multiple N-terminal htt fragments accumulate
in the nucleus [60]. The association between nuclear accu-
mulation of mutant htt and disease progression is clear
from several HD mouse models. In HD knock-in mouse
models, mutant htt accumulates preferentially in the
nuclei of striatal neurons and forms more prominent
aggregates as the disease progresses [43,58]. A progressive
phenotype is also associated with the nuclear accumula-
tion of an amino-terminal cleavage fragment in a trans-
genic mouse model with inducible expression of full-Molecular Neurodegeneration 2006, 1:19 http://www.molecularneurodegeneration.com/content/1/1/19
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length mutant huntingtin [67]. Targeting mutant htt with
nuclear localization sequences to direct mutant htt in the
nucleus of mouse brains produces neurological pheno-
types [68,69]. Furthermore, prevention of htt cleavage by
mutating the caspase-6 site can alleviate neurological phe-
notypes and delay the nuclear accumulation of mutant htt
in YAC transgenic mice [56].
Studies of N-terminal htt fragments have failed to find
that these fragments contain nuclear localization
sequences. Thus, N-terminal htt fragments may passively
enter the nucleus, but expanded polyQ repeats prevent
their export from the nucleus [70]. The presence of
mutant htt fragments in the nucleus and various cleavage
sites in the N-terminal region of htt [61-64,71] also sup-
port the notion that proteolysis of htt leads to generation
of toxic htt fragments. Consistently, smaller N-terminal
htt fragments appear to be more toxic than large-sized
fragments in both cultured cells [72] and transgenic ani-
mals [28,29,40]. For example, R6/2 mice that express
exon1 (1–67 amino acids) with 115–150Q show more
severe neurological phenotypes than transgenic mice that
express longer-fragment (N171-82Q) or full-length
mutant htt [28,29,56]. In addition, transgenic mice
expressing smaller htt fragments show more abundant htt
inclusions in the nucleus than those expressing longer htt
fragments.
The aberrant nuclear accumulation of mutant htt is likely
to cause gene transcriptional dysregulation. Indeed, sev-
eral nuclear transcription factors are found to bind htt
[19,73]. Of these, the coactivators cAMP response ele-
ment-binding protein(CREB)-binding protein (CBP) and
specificity protein 1 (Sp1) are particularly important for
neuronal function. Deletion of CREB in the brain causes
selective neurodegeneration in the hippocampus and
striatum [74]. Many neuronal genes that lack a TATA box
require Sp1 for their transcription [75]. Dysregulation of
gene expression mediated by CBP and Sp1 have been
found in HD mouse brains [76].
The interactions of mutant htt with transcription factors
may occur at various binding sites. Many transcription
factors contain a polyQ-rich domain. Since CBP is
recruited into aggregates formed by different polyQ pro-
teins, such as the androgen receptor [77], the SCA3 [78],
and the DRPLA [79] proteins, it has been thought that the
polyQ domain is the binding site to interact with other
polyQ proteins. In support of this idea, a number of tran-
scription factors containing polyQ or proline-rich
domains, including CBP [79,80], TBP [81,82], and
TAF130 [83], have been found in nuclear polyQ inclu-
sions. However, subsequent studies showed that the
acetyltransferase domain in CBP interacts with htt
[78,80], which led to the finding that inhibition of his-
tone deacetylase (HDAC) or promotion of histone
acetylation ameliorates neurodegeneration in cellular and
fly models [80] and motor deficits in a mouse model of
HD [84]. The colocalization of some transcription factors
in nuclear polyQ inclusions also led to the idea that
recruitment of transcription factors into polyQ inclusions
reduces the level of these transcription factors. After exam-
ining several HD mouse models, however, researchers
were unable to find decreased levels of CBP in sympto-
matic mouse brains [54,85]. In addition, altered expres-
sion of a number of genes was not necessarily associated
with the formation of htt aggregates in HD mice [76] and
could occur in cell models in the absence of nuclear inclu-
sions [86,87]. Thus, it is likely that soluble or misfolded
htt may interact with transcription factors to alter tran-
scriptional activity. This idea is further supported by the
finding that soluble mutant htt reduces the binding of Sp1
to DNA [88,89].
Several other important transcription factors are also
implicated for their interactions with htt in the nucleus.
TAF130, which is an important transcription factor that
binds TBP and is involved in Sp1 and CREB-dependent
gene transcription, binds htt [88] and other polyQ pro-
teins, such as the DRPLA and SCA3 proteins [83]. TBP,
which is a basal transcriptional factor containing a polyQ
stretch, is also found to colocalize with polyQ inclusions
[81,82] and to associate with htt in vitro [90]. In addition,
htt interacts with p53 in the nucleus to affect cell viability
[91]. Recent studies also show that mutant htt can affect
PGC-1alpha (peroxisome proliferator-activated receptor
gamma coactivator 1alpha), which transduces many
physiological stimuli into specific metabolic programs by
stimulating mitochondrial activity. Lack of this transcrip-
tion factor causes degeneration in different types of cells,
including striatal neurons [92,93]. Cui et al's study
showed that mutant htt associates with the promoter of
the PGC-1alpha gene to affect its expression, thereby
mediating striatal degeneration [94]. The interference of
PGC-1alpha function is also observed in brown fat tissues
in HD transgenic mice [95]. These studies suggest PGC-
1alpha as a new therapeutic target in HD. Combined,
there is ample evidence that mutant htt acts in the nucleus
to affect gene transcription.
Cytoplasmic effect of mutant huntingtin
Earlier studies have reported that mutant htt increases cas-
pase activity [96-99] and affects various signaling path-
ways [100-104]. These findings suggest that mutant htt
also acts in the cytoplasm to affect cellular functions. Thus
began an intensive search to reveal the interactions
between htt and cytoplasmic proteins. By means of the
yeast two-hybrid screen and in vitro binding assays, a
number of cytoplasmic proteins were found to interact
with htt [14,18,105]. Of these, htt-associated protein 1Molecular Neurodegeneration 2006, 1:19 http://www.molecularneurodegeneration.com/content/1/1/19
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(HAP1) and htt-interacting protein 1 (HIP1) have been
studied extensively. Both proteins may be involved in
intracellular trafficking. HAP1 binds more tightly to
mutant htt than to normal htt [106,107]. HAP1 also asso-
ciates with both dynactin p150, which is involved in
microtubule-dependent retrograde transport [108,109],
and kinesin light chain 2 [110], which is involved in
anterograde transport. Several studies suggest that HAP1
participates in the trafficking or endocytosis of membrane
receptors, including those for epidermal growth factor
[111], type 1 inositol (1,4,5)-triphosphate receptor
(InsP3R1) [103], GABA [112], and nerve growth factor
(NGF) [113]. Like htt, HAP1 is located at various subcel-
lular sites, including microtubules and synaptic vesicles in
axonal terminals [22]. Mice lacking HAP1 often die at
postnatal day 3 [114,115], which is likely as a result of
neuronal degeneration in the hypothalamus [115]. The
hypothalamic function of HAP1 appears to be critical for
feeding behavior and metabolism [116], and its dysfunc-
tion may contribute to hypothalamic pathology or degen-
eration in HD [32,115,117].
HIP1 is also important for assembly and function of the
cytoskeleton and endocytosis [118] and binds clathrin
and alpha-adaptin subunit AP-2 [119-121]. The interac-
tions of HIP1 with these proteins may constitute a protein
complex involved in clathrin-mediated endocytosis.
Unlike HAP1, HIP1 binds mutant htt weakly [118]. This
suggests that HIP1 requires interaction with htt for nor-
mal function, whereas dissociation from mutant htt may
impair its function.
Although the interactions of htt with HAP1, HIP1, and
other cytoplasmic proteins suggest that htt is involved in
intracellular trafficking, more compelling evidence has
come from the studies of trafficking function in cells that
express mutant htt. Recent studies show that normal Dro-
sophila htt functions in the axonal transport pathway and
that polyQ expansion causes soluble htt to recruit more
microtubule transporter proteins, thereby reducing the
soluble pool of these proteins in axons [122]. In cultured
neurons, htt is involved in HAP1-associated axonal trans-
port of brain-derived neurotrophic factor (BDNF) both
anterogradely and retrogradely, and mutant htt disrupts
this transport [107]. Trushina et al (2004) also found that
expression of full-length mutant htt impaired vesicular
and mitochondrial trafficking in mouse neurons [123].
Similarly, expanded polyQ in the first exon of htt can
cause axonal abnormalities prior to cell body degenera-
tion in Caenorhabditis elegans, even in the absence of cell
body aggregates [124]. Also, expressing polyQ proteins in
cultured neurons shows that mutant htt can affect axonal
transport [125].
Because of the limited space of neuronal processes,
neuropil aggregates themselves may physically impair
trafficking or affect neurotransmitter release [126,127].
Recently, htt aggregates were found to affect the trafficking
of mitochondria [128], suggesting that neuropil aggre-
gates could also impair the trafficking of other organelles.
There is strong evidence for the pathological role of polyQ
aggregates in axonal degeneration. As mentioned previ-
ously, abundant dystrophic neurites are evident in pre-
symptomatic postmortem HD patient brains in the cortex
and the striatum, the two areas most affected in HD
[44,45]. Dystrophic neurites are abnormal structures out-
side the cell body and are potentially derived from degen-
erated axons or dendrites. In HD repeat knock-in mice,
which do not show obvious neurological phenotypes,
large htt aggregates are found in degenerating axons and
axonal terminals [40,52].
The finding of axonal dysfunction or degeneration in var-
ious HD models provides a compelling argument that
axonal dysfunction is an early neuropathological event in
HD [52,122,125,129]. Degeneration of axons often pre-
cedes the death of the cell body and is commonly associ-
ated with a variety of neurodegenerative disorders,
including Wallerian degeneration, Alzheimer's disease,
and Parkinson's disease [130,131]. The degeneration of
the distal ends of axons can lead to defective neuronal
interaction, abnormal synaptic transmission, and an
impaired supply of growth factors to the cell body, even-
tually causing the loss of the neuronal body.
Cell-cell interactions and Huntington's disease
Cell-cell interactions constitute the complex circuitry that
regulates the normal function of neurons in various brain
regions. Previous studies have focused on the autonomic
effect of mutant htt on neuronal function, while scant
attention has been paid to the role of cell-cell interactions
in HD pathogenesis. Gu et al created conditional HD mice
that express exon1 mutant htt in discrete neuronal popu-
lations. They found that mutant htt forms aggregates in a
cell-autonomous manner. However, progressive motor
deficits and cortical neuropathology are observed only
when mutant htt is expressed in multiple neuronal types,
not when mutant htt is restricted to cortical pyramidal
neurons [41]. Since the transgenic htt is expressed under a
neuronal promoter in their study, their findings provide
compelling evidence for involvement of neuronal cell
interactions in HD pathology.
Glial cells constitute 90% of the cells in the brain and pro-
vide nutrition, growth factors, and structural support for
neurons to survive and function normally. They also pro-
tect against excitotoxicity by removing excess excitatory
neurotransmitters from the extracellular space [132-134].
This protective function may be particularly relevant toMolecular Neurodegeneration 2006, 1:19 http://www.molecularneurodegeneration.com/content/1/1/19
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the neuropathology of HD, since excitotoxicity has been a
long-standing theory to account for the pathogenesis of
HD [135-137]. As discussed above, MSNs in the striatum
are largely innervated by glutamatergic axons and are pref-
erentially degenerated in HD. Glutamate activates iono-
tropic glutamate receptors, specifically the N-methyl-D-
aspartate (NMDA) and non-NMDA receptors (ie, AMPA/
kainate). Overstimulation of glutamate receptors by high
levels of extracellular glutamate induces excitotoxicity
[138]. Administration of NMDA receptor agonists to the
striatum of animals causes a selective loss of MSNs and
produces neurological symptoms similar to those seen in
HD patients [136,139], whereas NMDA receptor antago-
nists effectively reduce excitotoxicity in HD animal mod-
els [140]. Furthermore, HD transgenic mouse models
show increased NMDA receptor activity in neurons
[102,141,142]. Because of the abundant glutamatergic
innervation to MSNs, cell-cell interactions may be partic-
ularly important for the vulnerability of MSNs to extracel-
lular glutamate.
Clearance of extracellular excitatory neurotransmitters is
largely carried out by astrocytes, which are the major sub-
type of glia. These cells contain membrane receptors
(GLT-1 and GLAST) that transport extracellular glutamate
into the cytoplasm, where glutamate is subsequently
metabolized by glutamine synthase [143]. Some studies
have suggested that the function of GLT-1 is impaired in
HD. HD mouse brains have an increased extracellular
glutamate concentration and a reduced expression level of
GLT-1 [144,145]. Transgenic mutant htt in Drosophila glia
reduces the expression of glutamate transporter and short-
ens the life span of the fly [146]. Shin et al provided evi-
dence that mutant htt is also expressed in glial cells in the
brains of both HD mice and HD patients. They further
demonstrated that mutant htt reduces glial glutamate
uptake, as well as the protection it confers against htt-
mediated neurotoxicity [147]. These studies suggest that
glia-neuron interactions also play important roles in the
pathogenesis of HD.
Summary
Since the discovery of the gene mutation in HD, there
have been great strides towards elucidating the pathogen-
esis of this disease. It has become clear that polyQ expan-
sion can cause mutant htt to misfold and to aggregate.
Misfolded htt abnormally interacts with a variety of pro-
teins and also accumulates in the nucleus and neuronal
processes. Furthermore, it is evident that proteolysis of htt
is required for the aggregation and misfolding of mutant
htt. Accordingly, many cleavage sites have been found in
the N-terminal region of htt, and tremendous efforts have
been put forth to find a means of blocking the generation
of toxic htt fragments. The present review focuses on the
effects of mutant htt in the nucleus and cytoplasm. Given
its localization in both the nucleus and neuronal proc-
esses and its interactions with a variety of proteins, mutant
htt is likely to affect a number of targets. Thus, it is con-
ceivable that mutant htt engages multiple pathogenic
pathways.
An important issue facing researchers is how to sort out
the major pathogenic pathways as targets for developing
therapeutic strategies. For example, which is the more crit-
ical for neuronal dysfunction and neurodegeneration, the
nuclear or the cytoplasmic effect of mutant htt? Answering
this question would require a better understanding than
we currently possess of mutant htt's effects in different
types of cells and at different stages of the disease. The
preferential localization of mutant htt in the nucleus of
striatal neurons suggests that the nuclear effect of mutant
htt or gene transcriptional dysregulation may affect neuro-
nal function at the early stage of the disease. In other types
of cells, mutant htt in the cytoplasm could also impair
neuronal function without showing nuclear accumula-
tion. In the case of mitochondrial dysfunction and excito-
toxicity, which represent an early theory of HD
pathogenesis, mutant htt may act in the nucleus to affect
the expression of mitochondrial proteins. It can also
directly impair mitochondrial function in the cytoplasm.
In addition, cell-cell interactions and circuitry are critical
for the selective toxicity of mutant htt. For example, the
function of medium spiny neurons in the striatum is reg-
ulated to a great extent by BDNF and glutamate input
from cortical neurons. Their vulnerability is also influ-
enced by the ability of glial cells to protect against excito-
toxicity as well as the effect of mutant htt on NMDA
receptors. It is therefore likely that mutant htt affects mul-
tiple targets at different levels, leading to the selective neu-
rodegeneration of HD. Understanding how mutant htt
mediates these pathological pathways would help us to
find effective treatments for the disease.
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